Pharmaceutical startup Generic Aadhaar raised an undisclosed investment in its ongoing Pre-Series A from Japanese VC company Beyond Next Ventures.
Generic Aadhaar sells generic medicines through a network of franchisees. It also provides franchise owners with billing and inventory management software. The new funds will be used to expand the startup’s franchisee store count to 3000 across India. The startup will also expand its product offerings and invest in its digitisation strategy. According to the startup, it has diluted nearly 10% of its stake in the current funding round.
Disclaimer
We strive to uphold the highest ethical standards in all of our reporting and coverage. We StartupNews.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It’s possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.
Pharmaceutical startup Generic Aadhaar raised an undisclosed investment in its ongoing Pre-Series A from Japanese VC company Beyond Next Ventures.
Generic Aadhaar sells generic medicines through a network of franchisees. It also provides franchise owners with billing and inventory management software. The new funds will be used to expand the startup’s franchisee store count to 3000 across India. The startup will also expand its product offerings and invest in its digitisation strategy. According to the startup, it has diluted nearly 10% of its stake in the current funding round.
Disclaimer
We strive to uphold the highest ethical standards in all of our reporting and coverage. We StartupNews.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It’s possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.
